Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.48 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | SCN2B | O60939 | 2/20 | 0.39 |
| ▸ | SCN1A | P35498 | 2/20 | 0.39 |
| ▸ | SCN1B | Q07699 | 2/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | LCAT | P04180 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23387339 | 0.90 | NOTUM (0.44) | ACACBRIPK2PIK3CDPIK3CALCAT | |
| SCHEMBL23387232 | 0.90 | NOTUM (0.44) | ACACBRIPK2PIK3CDPIK3CALCAT | |
| SCHEMBL23387230 | 0.90 | NOTUM (0.44) | ACACBRIPK2PIK3CDPIK3CALCAT | |
| SCHEMBL23387356 | 0.88 | KMT2A (0.46) | ACACBRIPK2CHRNB4CHRNA3PIK3CD | |
| SCHEMBL23387357 | 0.88 | KMT2A (0.46) | ACACBRIPK2CHRNB4CHRNA3PIK3CD | |
| SCHEMBL23387268 | 0.85 | ACACB (0.45) | ACACBRIPK2CHRNB4CHRNA3PIK3CD | |
| SCHEMBL24244026 | 0.83 | ACACB (0.48) | ACACBRIPK2CHRM4CHRNB4CHRNA3 | |
| SCHEMBL21624687 | 0.82 | SIGMAR1 (0.48) | ACACBRIPK2CHRNB4CHRNA3GRIN2B | |
| SCHEMBL23387391 | 0.79 | ACACB (0.41) | ACACBRIPK2CHRNB4CHRNA3PIK3CD | |
| SCHEMBL23387390 | 0.79 | ACACB (0.41) | ACACBRIPK2CHRNB4CHRNA3PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-07-21 | — | — | US | disclosed |
| EP-3950059-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | Nippon Chemiphar Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| EP-3825303-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nippon Chemiphar Co., Ltd. (JP) | 2021-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | TRPV3, CACNA1G, TRPV2 | ACACB 3157/4885RIPK2 3339/4885CHRM4 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.